Rutherford Health - Exercise of Options London Stock Exchange
RNS Number : 8758W
Rutherford Health PLC
21 August 2020
 

Rutherford Health Plc

 

Exercise of Options

 

London, UK, 21 August 2020: Rutherford Health plc (the "Company" or "Rutherford ") announces that it has received a notice of exercise of options to acquire 38,462 Rutherford ordinary shares of 0.1p each ("Ordinary Shares") at a price of £1.00 per Ordinary Share.

 

Admission and dealings

Application has been made for the admission to trading on the AQSE Growth Market of the 38,462 Ordinary Shares with admission expected to take place on or around 27 August 2020 ("Admission").

 

Total voting rights

For the purposes of the Financial Conduct Authority's Disclosure Guidance and Transparency Rules ("DTRs"), following Admission the Company will have 198,011,700 Ordinary Shares in issue with voting rights attached. The Company holds no shares in treasury. This figure of  198,011,700  may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company, under the DTRs.

 

 

The directors of the Company accept responsibility for the content of this announcement.

 

 

Contacts

               

Rutherford Health plc

Michael Moran, Chief Executive Officer

Tel: +44 (0) 16 3381 0661

 

 

Grant Thornton (Corporate Adviser)

Colin Aaronson / Niall McDonald

Tel: +44 (0) 20 7383 5100

 

 

Media House International   

Tel: +44 (0) 7788 414 856 or +44 (0)20 7710 0020

Ramsay Smith

ramsay@mediahouse.co.uk

                               

 

About Rutherford Health plc

Rutherford Health plc is at the vanguard of advancing cancer care. Developing and building a network of oncology centres across the UK known as the Rutherford Cancer Centres, offering a comprehensive range of cancer treatments to patients.

 

The first centre in Newport, South Wales, was the first in the UK to offer high energy proton therapy. In addition, each centre also offers radiotherapy, chemotherapy, immunotherapy, diagnostic imaging and supportive care services.

 

As well as the Rutherford Cancer Centre North West, Rutherford Health plc (formerly known as Proton Partners International Limited) has opened three further centres - the Rutherford Cancer Centre South Wales in Newport, Rutherford Cancer Centre North East in Northumberland and the Rutherford Cancer Centre Thames Valley in Reading, with proton therapy available in those three centres.

 

Rutherford Health plc has partnered with world-leading healthcare technology providers to equip each centre with the very latest and innovative technology, including IBA, Philips and Elekta.

 

Rutherford Health plc was founded in 2015 by Mike Moran MBE and UK and international cancer experts, including Professor Edward Karol Sikora, former head of the World Health Organisation's cancer programme.

 

 

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NEXBUGDIIBDDGGB ]]>